Novo Nordisk: BARI-STEP semaglutide trial results posted; two new Phase 1 studies registered
Weekly roundup covers a completed UCL-led semaglutide trial with results posted, plus Novo Nordisk's new Phase 1 programs for NNC9836-0001 and NNC0642-1895.
Novo Nordisk's week included results from a collaborator-sponsored trial and two early-stage studies of its own moving forward.
- BARI-STEP, a Phase 3 trial sponsored by University College, London with Novo Nordisk as a collaborator, completed with primary completion on 2025-04-09 and results first posted on 2026-10-261. The trial tested semaglutide in patients with poor weight loss after bariatric surgery; the arms and interventions sections specify semaglutide 2.4mg/week subcutaneous injection for 68 weeks, including an initial 16-week escalation phase followed by 52 weeks of treatment at study dose1, with enrollment of 70 participants (actual)1.
- A Phase 1 study of NNC9836-0001, aimed at type 2 diabetes, is not yet recruiting, with an estimated start of 2026-10-212. The study plans to enroll 121 participants (estimated)2 and will assess treatment-emergent adverse events in both single ascending dose and multiple ascending dose cohorts2.
- A Phase 1 first-in-human study of NNC0642-1895 in healthy adults is recruiting, having started 2026-09-17 (actual)3. It plans to enroll 148 participants (estimated)3 and is testing safety, tolerability, and how the body responds to a single dose of NNC0642-1895 in healthy adults3.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.